ArticleFrontiers in public health2025
Elevating lived experience in overdose prevention: a community case study of Arizona's overdose data to action community advisory board.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The community representative council of the National Drug Abuse Treatment Clinical Trials Network: Co-design and early impact.Journal of substance use and addiction treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug overdose remains a leading cause of preventable death in the United States, with persistent inequities among populations that often face stigma and barriers to care. Traditional evaluation models often exclude people with lived and living experience (PWLE) of substance use from meaningful decision-making. Methods: To address this, the Arizona Department of Health Services (ADHS) implemented a community-based participatory evaluation model within its Overdose Data to Action in States (OD2A-S) program by establishing a Community Advisory Board (CAB). The CAB was designed to integrate lived experience into evaluation planning and interpretation, identify community-driven priorities, and guide program improvement. Members were recruited statewide through a nomination process and compensated. A licensed clinical social worker facilitated meetings using trauma-informed and healing-centered approaches. Participatory methods such as journey mapping and logic model development enabled members to translate personal and community experiences into actionable evaluation questions. Results: Between August 2024 and August 2025, the CAB met quarterly to prioritize evaluation of naloxone vending machines and peer navigation models. Members identified key barriers, including stigma, rural access, transportation, and lack of culturally responsive care, and provided input on equitable evaluation tools and communication strategies. A composition survey confirmed strong representation of individuals in recovery (86%) and people of color (88%), though rural and tribal, medically assisted treatment, and veteran perspectives remain limited or not represented. Discussion: Early lessons demonstrate that compensated, trauma-informed engagement fosters trust, accountability, and practical insights that strengthen evaluation quality and relevance. Challenges include administrative delays in payment, limited generalizability due to small membership, and the need for sustainable funding to expand representation. Conclusion: Arizona's OD2A-S CAB provides a replicable model for integrating lived experience into state-level overdose prevention. By positioning PWLE as co-evaluators rather than participants, this model advances equity, builds system trust, and strengthens the translation of data into action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.